- Home
- MITT vs EDIT Comparison
MITT vs EDIT Comparison
Compare MITT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITT
- EDIT
- Stock Information
- Founded
- MITT 2011
- EDIT 2013
- Country
- MITT United States
- EDIT United States
- Employees
- MITT N/A
- EDIT N/A
- Industry
- MITT Real Estate Investment Trusts
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MITT Real Estate
- EDIT Health Care
- Exchange
- MITT Nasdaq
- EDIT Nasdaq
- Market Cap
- MITT 230.0M
- EDIT 269.8M
- IPO Year
- MITT 2011
- EDIT 2016
- Fundamental
- Price
- MITT $7.17
- EDIT $3.06
- Analyst Decision
- MITT Strong Buy
- EDIT Buy
- Analyst Count
- MITT 5
- EDIT 11
- Target Price
- MITT $8.50
- EDIT $4.56
- AVG Volume (30 Days)
- MITT 152.6K
- EDIT 3.0M
- Earning Date
- MITT 11-04-2025
- EDIT 10-31-2025
- Dividend Yield
- MITT 11.75%
- EDIT N/A
- EPS Growth
- MITT N/A
- EDIT N/A
- EPS
- MITT 0.86
- EDIT N/A
- Revenue
- MITT $83,509,000.00
- EDIT $38,901,000.00
- Revenue This Year
- MITT N/A
- EDIT N/A
- Revenue Next Year
- MITT $14.27
- EDIT N/A
- P/E Ratio
- MITT $8.33
- EDIT N/A
- Revenue Growth
- MITT 25.02
- EDIT N/A
- 52 Week Low
- MITT $5.63
- EDIT $0.91
- 52 Week High
- MITT $7.97
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- MITT 46.01
- EDIT 41.49
- Support Level
- MITT $7.00
- EDIT $2.94
- Resistance Level
- MITT $7.49
- EDIT $3.37
- Average True Range (ATR)
- MITT 0.16
- EDIT 0.31
- MACD
- MITT 0.01
- EDIT -0.12
- Stochastic Oscillator
- MITT 37.25
- EDIT 13.01
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.